Boston Scientific Co. (NYSE:BSX) Shares Sold by Swiss National Bank

Swiss National Bank lessened its position in shares of Boston Scientific Co. (NYSE:BSX) by 1.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,578,700 shares of the medical equipment provider’s stock after selling 45,600 shares during the quarter. Swiss National Bank’s holdings in Boston Scientific were worth $264,695,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. BSW Wealth Partners grew its holdings in Boston Scientific by 2.3% during the 4th quarter. BSW Wealth Partners now owns 7,398 shares of the medical equipment provider’s stock valued at $428,000 after buying an additional 165 shares during the last quarter. Valley National Advisers Inc. boosted its stake in shares of Boston Scientific by 2.3% during the 4th quarter. Valley National Advisers Inc. now owns 7,526 shares of the medical equipment provider’s stock worth $435,000 after purchasing an additional 170 shares during the last quarter. Whitaker Myers Wealth Managers LTD. grew its holdings in shares of Boston Scientific by 4.6% during the fourth quarter. Whitaker Myers Wealth Managers LTD. now owns 4,093 shares of the medical equipment provider’s stock worth $237,000 after buying an additional 179 shares in the last quarter. Brighton Jones LLC raised its position in shares of Boston Scientific by 5.4% in the third quarter. Brighton Jones LLC now owns 3,999 shares of the medical equipment provider’s stock valued at $211,000 after buying an additional 205 shares during the last quarter. Finally, Altfest L J & Co. Inc. lifted its stake in shares of Boston Scientific by 1.6% during the third quarter. Altfest L J & Co. Inc. now owns 13,298 shares of the medical equipment provider’s stock valued at $702,000 after buying an additional 208 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Edward J. Ludwig sold 7,000 shares of the business’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $65.03, for a total value of $455,210.00. Following the completion of the sale, the director now directly owns 41,374 shares of the company’s stock, valued at $2,690,551.22. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $66.89, for a total transaction of $467,092.87. Following the completion of the sale, the executive vice president now owns 56,508 shares of the company’s stock, valued at approximately $3,779,820.12. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Edward J. Ludwig sold 7,000 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $65.03, for a total transaction of $455,210.00. Following the completion of the transaction, the director now directly owns 41,374 shares in the company, valued at approximately $2,690,551.22. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 78,384 shares of company stock worth $5,395,560. 0.50% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. TD Cowen boosted their price target on Boston Scientific from $65.00 to $77.00 and gave the company an “outperform” rating in a report on Thursday, March 7th. Barclays upped their target price on Boston Scientific from $70.00 to $78.00 and gave the company an “overweight” rating in a research note on Friday, April 26th. Royal Bank of Canada raised their price target on Boston Scientific from $78.00 to $82.00 and gave the stock an “outperform” rating in a research note on Thursday, April 25th. Citigroup upped their price objective on shares of Boston Scientific from $79.00 to $85.00 and gave the company a “buy” rating in a research note on Thursday, April 25th. Finally, Wells Fargo & Company raised their target price on shares of Boston Scientific from $72.00 to $82.00 and gave the stock an “overweight” rating in a research report on Thursday, April 25th. Three investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Boston Scientific has an average rating of “Moderate Buy” and a consensus target price of $75.09.

Boston Scientific Stock Up 1.2 %

BSX traded up $0.83 on Friday, reaching $72.86. The company’s stock had a trading volume of 7,452,079 shares, compared to its average volume of 6,661,660. Boston Scientific Co. has a 1 year low of $48.35 and a 1 year high of $74.39. The business’s 50 day moving average is $68.30 and its 200 day moving average is $61.11. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.32 and a quick ratio of 0.82. The stock has a market cap of $109.29 billion, a price-to-earnings ratio of 61.22, a price-to-earnings-growth ratio of 2.48 and a beta of 0.77.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share for the quarter, topping analysts’ consensus estimates of $0.51 by $0.04. The business had revenue of $3.73 billion during the quarter, compared to the consensus estimate of $3.59 billion. Boston Scientific had a net margin of 12.06% and a return on equity of 16.63%. During the same quarter last year, the company earned $0.45 earnings per share. As a group, research analysts forecast that Boston Scientific Co. will post 2.32 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.